This comment letter responds to the FDA’s proposed rule on the protection of human subjects and Institutional Review Boards, intended to harmonize FDA regulations with the Common Rule. UC requests a 60-day extension of the comment period, for a total of 120 days, to allow adequate consultation with researchers, administrators, and compliance and privacy experts regarding the proposal’s implications for human-subject research protections and oversight.
